FLOVENT HFA METERED-DOSE AEROSOL

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

FLUTICASONE PROPIONATE

Pieejams no:

GLAXOSMITHKLINE INC

ATĶ kods:

R03BA05

SNN (starptautisko nepatentēto nosaukumu):

FLUTICASONE

Deva:

50MCG

Zāļu forma:

METERED-DOSE AEROSOL

Kompozīcija:

FLUTICASONE PROPIONATE 50MCG

Ievadīšanas:

INHALATION

Vienības iepakojumā:

120 DOSES

Receptes veids:

Prescription

Ārstniecības joma:

ADRENALS

Produktu pārskats:

Active ingredient group (AIG) number: 0124685001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2001-07-18

Produkta apraksts

_ _
_Page 1 of 57_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
FLOVENT HFA
fluticasone propionate inhalation aerosol
50, 125, and 250 mcg/metered dose
PR
FLOVENT DISKUS
fluticasone propionate powder for inhalation
100, 250, and 500 mcg/blister
Corticosteroid for Oral Inhalation
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Initial Approval:
July 31, 1995
Date of Revision:
March 1, 2021
Submission Control No: 243742
_©_
_2021 GSK group of companies or its licensor _
_AEROCHAMBER PLUS is a trademark owned by Trudell Medical
International. All other trademarks are owned by or licensed _
_to the GSK group of companies. _
_ _
_Page 2 of 57_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE
NOT LISTED.
TABLE OF CONTENTS ..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4
1
INDICATIONS
....................................................................................................................4
1.1 Pediatrics
........................................................................................................................4
1.2 Geriatrics
........................................................................................................................4
2
CONTRAINDICATIONS ..................................................................................................4
4 DOSAGE AND ADMINISTRATION .......................................................................................4
4.1 Dosing Considerations
...................................................................................................5
4.2 Recommended Dose and Dosage Adjustment
...............................................................5
4.4 Administration
...............................................................................................................